Full Press Release Details
Appoints Bas van der Baan as President and Chief Executive Officer
Veteran Bas van der Baan Brings Precision Oncology Expertise;
John S. Kovach Named Executive Chairman
CA, September 26, 2023 -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT
and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that
Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors,
effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds
John S. Kovach, M.D., 87, who founded the Company in 2005 and was named Executive Chairman. Dr. Kovach will continue as the Company's
Chief Scientific Officer. Both Dr. Kovach and Mr. van der Baan will continue in their roles as members of the Board of Directors of LIXTE.
van der Baan, 51, has more than 20 years of experience in the biotechnology industry, with a key focus on oncology and diagnostics. Most
recently, he was the Chief Clinical and Business Development Officer of Agendia, Inc. in Irvine, California and Amsterdam, Netherlands.
In that role, Mr. van der Baan was instrumental in the initiation and execution of numerous clinical trials that led to full commercialization
and adoption of precision molecular oncology diagnostics. He initiated the launch of Agendia's business operations in the United
States and has broad knowhow in clinical development, both in the United States and in Europe.
has extensive expertise managing products from clinical development to commercialization, and along with his involvement in establishing
partnerships with pharmaceutical companies, he will be highly valuable to LIXTE in the next phase of the Company's development,"
said Dr. Kovach. "I look forward to working closely with Bas in my new role as Executive Chairman, as we continue to focus on expediting
the clinical development of our promising lead compound, LB-100."
my tenure serving on the Board of Directors, I have worked with the entire LIXTE team and am
impressed with the progress made with LB-100. I am honored and delighted to accept this position with LIXTE as the Company continues
its journey through the clinical trial process," Mr. van der Baan said. "I look forward to leading LIXTE in its mission to
improve medical outcomes for patients undergoing various chemotherapies and immunotherapies, and to establishing and commercializing
what we believe to be the significant clinical potential of LB-100."
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors.
The Company's innovative approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing
new treatment options for patients. At the core of the Company's therapy is LB-100, the Company's proprietary compound
that acts as an inhibitor of the PP2A phosphatase with a favorable toxicity profile. LB-100 promotes the production of neoantigens
and cytokines, boosts T-cell proliferation, and disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment
outcomes. The Company is conducting multiple clinical trials for solid tumors with unmet medical needs. LIXTE's unique approach
has no known competitors and is covered by a comprehensive patent portfolio.
information about LIXTE can be obtained at www.lixte.com and by reviewing the Company's filings with the United States Securities
and Exchange Commission at https://www.sec.gov.
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing
development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, and the patent and
legal costs to protect and maintain the Company's intellectual property worldwide, are all forward-looking statements. These statements
are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other comparable terminology. The Company
believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available
to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct
or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently
subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated
in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory
policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at https://www.sec.gov.
more information about LIXTE, Contact:
Investor Phone: (888) 289-5533
Inc. Investor Relations
Roger Pondel or Laurie Berman: (310)